FDA Approves Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone in Newly Diagnosed Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-approves-sarclisa-isatuximab-with-vrd-for-ndmm)